Clinical Trial Update: A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

A Phase 2, single-center clinical trial investigating bortezomib for immune thrombocytopenia, sponsored by Shandong University; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN